Novavax has been a punching bag for the market lately — two consecutive Zacks headlines about the stock underperforming the broader market tells you everything about sentiment right now. But sentiment and value aren't the same thing, and at $8.43 with an analyst consensus target of $14, there's a wide gap between where traders are pricing this and where the fundamentals suggest it could go. That gap is exactly where this trade lives.
The setup: sell the $8.50 put expiring July 24 for $0.31 premium. Eight days to expiration. Delta is -0.52, meaning the market currently prices this as essentially a coin flip at the strike — which sounds scary until you zoom out and notice that the 200-day moving average sits at $8.54. NVAX has been using that level as a magnet for months. You're selling a put just below long-term technical support with a week on the clock.
The IV story here is worth pausing on. At 55.2% implied volatility, biotech premium is doing what biotech premium does — pricing in chaos that often doesn't materialize on a weekly timeframe. That 55% IV on an 8-DTE trade is what's generating a $0.31 premium on an $8.50 strike. Annualize that yield and you're looking at something well north of 20% on committed capital. Novavax isn't announcing a phase 3 trial result next week. The near-term catalyst risk is manageable.
The bear case is real and shouldn't be ignored. Profit margins are negative at -14.7%, Beta is 2.43, and the 50-day MA at $9.30 is comfortably above current price — meaning the trend is down. This is not a quality compounder. It's a beaten-down biotech trading near multi-year lows where the asymmetry of selling premium at a strike with historical support makes more sense than trying to call a directional bottom. If NVAX catches a bid and closes above $8.50 on the 24th, you keep the full $0.31. If it slides below and you get assigned, you're long a stock at an effective cost basis of $8.19 — below the 200-day.
Watch the broader biotech tape and any company-specific news around its COVID vaccine pipeline. A surprise regulatory headline in either direction could move NVAX fast given that beta. The trade is short-duration for a reason.
Today's Atlas Trades
TSM — Short Put
- Strike: $385.0
- Expiration: 2026-08-14
- Premium: $11.97
- Stock Price: $419.48
- IV: 57.7%
- Delta: -0.265
- DTE: 29
TCOM — Short Put
- Strike: $40.0
- Expiration: 2026-08-21
- Premium: $1.23
- Stock Price: $42.87
- IV: 47.3%
- Delta: -0.286
- DTE: 36
PGR — Short Put
- Strike: $195.0
- Expiration: 2026-08-21
- Premium: $6.27
- Stock Price: $205.22
- IV: 43.5%
- Delta: -0.319
- DTE: 36
NET — Short Put
- Strike: $270.0
- Expiration: 2026-07-24
- Premium: $7.05
- Stock Price: $273.04
- IV: 53.5%
- Delta: -0.424
- DTE: 8
RBRK — Short Put
- Strike: $70.0
- Expiration: 2026-08-21
- Premium: $1.73
- Stock Price: $80.38
- IV: 58.5%
- Delta: -0.194
- DTE: 36
HPQ — Short Put
- Strike: $23.0
- Expiration: 2026-08-21
- Premium: $0.76
- Stock Price: $23.75
- IV: 38.7%
- Delta: -0.361
- DTE: 36
WRBY — Short Put
- Strike: $27.5
- Expiration: 2026-07-24
- Premium: $0.77
- Stock Price: $27.91
- IV: 59.6%
- Delta: -0.412
- DTE: 8
SE — Short Put
- Strike: $110.0
- Expiration: 2026-08-07
- Premium: $4.4
- Stock Price: $111.36
- IV: 47.7%
- Delta: -0.427
- DTE: 22
MSBT — Short Put
- Strike: $18.0
- Expiration: 2026-08-21
- Premium: $0.74
- Stock Price: $18.63
- IV: 46.0%
- Delta: -0.368
- DTE: 36
NVAX — Short Put
- Strike: $8.5
- Expiration: 2026-07-24
- Premium: $0.31
- Stock Price: $8.43
- IV: 55.2%
- Delta: -0.520
- DTE: 8
JPM — Short Put
- Strike: $350.0
- Expiration: 2026-08-14
- Premium: $10.32
- Stock Price: $346.91
- IV: 23.7%
- Delta: -0.522
- DTE: 29
MKC — Short Put
- Strike: $50.0
- Expiration: 2026-08-21
- Premium: $1.69
- Stock Price: $50.92
- IV: 34.9%
- Delta: -0.399
- DTE: 36